PTJ
NTLA icon

Paul Tudor Jones’s Intellia Therapeutics NTLA Stock Holding History

Paul Tudor Jones’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$217K Buy
+12,800
New +$179K ﹤0.01% 3287

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Paul Tudor Jones's NTLA Position: Q2 2026 in Review

Paul Tudor Jones increased its Intellia Therapeutics (NTLA) stake by 31% in Q2 2026, buying an estimated $387K and bringing the position to 116,908 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #1949.

Paul Tudor Jones first reported a position in NTLA in Q2 2021 and has held it in 14 quarters since. 326 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Paul Tudor Jones held 116,908 shares of Intellia Therapeutics worth $1.98M as of Q2 2026.
  • Paul Tudor Jones bought 27,685 Intellia Therapeutics shares in Q2 2026, an estimated $387K.
  • Intellia Therapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1949 holding.
  • Paul Tudor Jones first reported a position in Intellia Therapeutics in Q2 2021 and has held it in 14 quarters since.
  • 326 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.